New skin ointment takes first step toward treating inflammatory conditions
NCT ID NCT07673458
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial tests whether a new ointment called YR001 is safe and tolerable when applied to the skin of healthy Chinese adults. The ointment contains a substance that blocks a specific potassium channel involved in immune cell activity. Researchers compare the active ointment to a placebo to check for side effects and measure how much of the drug enters the bloodstream. The study involves 18 participants and lasts about 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YR001 (Kv1.3 potassium channel blocker) topical ointment
What this could lead to
If safe, this could pave the way for a new topical treatment for inflammatory skin conditions like psoriasis or eczema.
What could go wrong
This is an early Phase 1 safety study in healthy people, not patients. It does not test effectiveness, and the ointment may cause skin irritation or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei CNPC Central Hospital
RECRUITINGLangfang, Hebei, 065000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••